References
1. Voysey M, Clemens SAC, Madhi SA,
Weckx LY, Folegatti PM, Aley PK, et al. 2021 Safety and efficacy of the
ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim
analysis of four randomised controlled trials in Brazil, South Africa,
and the UK. Lancet 397:99-111.
2. Furer V, Zisman D, Kibari A, Rimar
D, Paran Y, Elkayam O. 2021 Herpes zoster following BNT162b2 mRNA
Covid-19 vaccination in patients with autoimmune inflammatory rheumatic
diseases: a case series. Rheumatology (Oxford).
3. Walter R, Hartmann K, Fleisch F,
Reinhart WH, Kuhn M. 1999 Reactivation of herpesvirus infections after
vaccinations? The Lancet 353:810.
4. Kim SH, Wi YM. 2021 Adverse Events
in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or
BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience. J Korean
Med Sci 36:e107.
5. Fernandez-Nieto D, Ortega-Quijano
D, Suarez-Valle A, Burgos-Blasco P, Jimenez-Cauhe J, Fernandez-Guarino
M. 2020 Comment on:“To consider varicella-like exanthem associated with
COVID-19, virus varicella zoster and virus herpes simplex must be ruled
out. Characterization of herpetic lesions in hospitalized COVID-19
patients”. J Am Acad Dermatol 83:e257-e9.
6. Le Balc’h P, Pinceaux K, Pronier C,
Seguin P, Tadié J-M, Reizine F. 2020 Herpes simplex virus and
cytomegalovirus reactivations among severe COVID-19 patients. Crit Care
24:1-3.
7. Schepis D, D’amato M, Studahl M,
Bergström T, Kärre K, Berg L. 2009 Herpes simplex virus infection
downmodulates NKG2D ligand expression. Scand J Immunol 69:429-36.
8. Nausch N, Cerwenka A. 2008 NKG2D
ligands in tumor immunity. Oncogene 27:5944-58.
9. González S, López-Soto A,
Suarez-Alvarez B, López-Vázquez A, López-Larrea C. 2008 NKG2D ligands:
key targets of the immune response. Trends Immunol 29:397-403.
10. Ewer KJ, Barrett JR. 2021 T cell
and antibody responses induced by a single dose of ChAdOx1 nCoV-19
(AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med 27:270-8.